Signs Point To Banner Year For Novel Approvals In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
With a month to go in 2014, FDA’s novel approval count has hit 43 – blowing past 2013’s full-year count of 35 new molecular entities and novel biologics from both CDER and CBER and within striking distance of 2012’s high of 45. Biologics are making the difference.
You may also be interested in...
Beyond "Breakthrough": FDA, Industry See Benefits For Drugs Outside Expedited Pathway
Pharmaceutical manufacturers and FDA have enthusiastically embraced the “breakthrough therapy” program as a way to more quickly bring new drugs with substantial effects to patients in need. With two years of program experience now under their belts, agency and industry representatives talk about learnings and best practices that could be applied to the development and review of drugs outside the program.
CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014
Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.